Clarithromycin is an Adjunct to Scaling and Root Planing (CASRCMI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02359721 |
Recruitment Status :
Completed
First Posted : February 10, 2015
Last Update Posted : February 10, 2015
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Periodontitis | Drug: tablet clarithromycin 500 mg (Clarino-500) orally | Phase 4 |
Background & Objectives: Along with conventional non-surgical periodontal therapy (NSPT) systemic antimicrobials may provide more effective treatment for chronic periodontitis by targeting tissue-invasive bacteria. The aim of this study was to evaluate the adjunctive effects of oral clarithromycin (CLM) to nonsurgical periodontal therapy for chronic periodontitis.
Materials and Methods: 30 patients were categorized into two groups: test group - Base line scaling and root planing(SRP) was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day. control group -only SRP done . Clinical parameters were recorded at baseline , 3 months, and six months interval .They included gingival index (GI), probing depth (PD), and clinical attachment level (CAL). Also microbial analysis of subgingival plaque samples was done at baseline, 3months and six months interval to estimate the levels of Pg and Aa bacteria using culture methods. Immunological parameter like estimation of C-Reactive protein was done in both groups at baseline 3 months and 6 months period. tests were used for statistical analysis.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Efficacy of Clarithromycin is an Adjunct to Scaling and Root Planing .A Clinical Microbiological and Immunological Study. |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | January 2013 |
Actual Study Completion Date : | December 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: test group
Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
|
Drug: tablet clarithromycin 500 mg (Clarino-500) orally
orally
Other Name: Clarino-500 |
No Intervention: control
scaling and root planing
|
- Efficacy of Clarithromycin, as measured by reduction Gingival bleeding [ Time Frame: 6 months ]0,3,6 months
- Efficacy of Clarithromycin, as measured by Pocket probing depth [ Time Frame: 6 months ]
- Efficacy of Clarithromycin, as measured by Clinical attachment gain [ Time Frame: 6 months ]
- c-reactive protein levels [ Time Frame: 6 months ]
- Pg and Aa bacterial count [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients age ranged between 30- 50 years with chronic periodontitis
- Patients with Probing Depth (PD)- >5mm, Clinical Attachment Level( CAL)- >3mm
- Systemically healthy individuals
Exclusion Criteria:
- Patients below the age of 30 years
- Patients who have undergone periodontal therapy 3 months prior to study
- Active /passive smokers
- Any antibiotic use 3 months prior to study
- Pregnant women and lactating mothers
- Un co- operative/ retarded patients
- Drug allergy/ other allergies
- Any systemic diseases
Publications of Results:
Other Publications:
Responsible Party: | J.surya prasanna, DR.J. SURYA PRASANNA, Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre |
ClinicalTrials.gov Identifier: | NCT02359721 History of Changes |
Other Study ID Numbers: |
RADHIKA DISSERTATION |
First Posted: | February 10, 2015 Key Record Dates |
Last Update Posted: | February 10, 2015 |
Last Verified: | January 2015 |
Colony forming units Antimicrobial agents Microbial colonization |
Clarithromycin Periodontitis Periodontal Diseases Mouth Diseases Stomatognathic Diseases Anti-Bacterial Agents |
Anti-Infective Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |